OrbiMed’s Shattuck Labs STTK Stock Holding History

OrbiMed’s Portfolio STTK Stock Details STTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$43.8M	Hold	6,306,127	–	–	0.81%	41
2026 Q1	$40.5M	Hold	6,306,127	–	–	0.8%	37
2025 Q4	$23M	Hold	6,306,127	–	–	0.47%	55
2025 Q3	$15.1M	Buy	+6,306,127	New	+$7.72M	0.35%	62

Other funds holding STTK

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

NCM

NEXTBio Capital Management Menlo Park, California $217M AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OrbiMed's STTK Position: Q2 2026 in Review

OrbiMed held its Shattuck Labs (STTK) position steady in Q2 2026 at 6,306,127 shares worth $43.8M. The position accounts for 0.81% of the portfolio, ranked #41.

OrbiMed first reported a position in STTK in Q3 2025 and has held it in 4 quarters since. 100 funds tracked by Wall St. Rank hold STTK as of Q2 2026.

OrbiMed held 6,306,127 shares of Shattuck Labs worth $43.8M as of Q2 2026.
OrbiMed left its Shattuck Labs share count unchanged in Q2 2026.
Shattuck Labs made up 0.81% of OrbiMed's portfolio in Q2 2026, its #41 holding.
OrbiMed first reported a position in Shattuck Labs in Q3 2025 and has held it in 4 quarters since.
100 funds tracked by Wall St. Rank held Shattuck Labs as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.